These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32940367)

  • 1. Development of cutaneous squamous cell carcinoma during pembrolizumab therapy.
    Mizutani K; Nakanishi T; Ikejiri M; Yuasa H; Matsushima Y; Kondo M; Nakai Y; Habe K; Nakatani K; Yamanaka K
    J Dermatol; 2021 Jan; 48(1):e7-e8. PubMed ID: 32940367
    [No Abstract]   [Full Text] [Related]  

  • 2. Eruptive porokeratosis during pembrolizumab treatment of invasive cutaneous squamous cell carcinoma.
    Maredia H; Simkin D; Soni A; Loss MJ
    Int J Dermatol; 2020 May; 59(5):e141-e142. PubMed ID: 31670381
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy.
    Larkins E; Blumenthal GM; Yuan W; He K; Sridhara R; Subramaniam S; Zhao H; Liu C; Yu J; Goldberg KB; McKee AE; Keegan P; Pazdur R
    Oncologist; 2017 Jul; 22(7):873-878. PubMed ID: 28533473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple and fulminant cutaneous squamous cell carcinomas in a Crohn's disease patient treated with immunosuppressants and adalimumab.
    Nancey S; Boschetti G; Cotte E; Cathey-Javouhay A; Laidet M; Chichery A; Francois Y; Glehen O; Flourié B
    Inflamm Bowel Dis; 2011 Apr; 17(4):1060-1. PubMed ID: 21391289
    [No Abstract]   [Full Text] [Related]  

  • 5. Case Report of Multiple Keratoacanthomas and Squamous Cell Carcinomas in a Patient Receiving Pembrolizumab.
    Chaudhari S; Leon A; Levin E; Neuhaus I; Liao W
    J Drugs Dermatol; 2017 May; 16(5):513-515. PubMed ID: 28628690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System.
    Liu Y; Fitzgerald B; Perry E; Pathak A; Chao HH
    J Investig Med High Impact Case Rep; 2019; 7():2324709619850216. PubMed ID: 31132886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab for Treatment of a Patient With Multiple Cutaneous Squamous Cell Carcinomas and Recessive Dystrophic Epidermolysis Bullosa.
    Piccerillo A; El Hachem M; De Vito R; De Luca EV; Peris K
    JAMA Dermatol; 2020 Jun; 156(6):708-710. PubMed ID: 32320041
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas.
    Maubec E; Boubaya M; Petrow P; Beylot-Barry M; Basset-Seguin N; Deschamps L; Grob JJ; Dréno B; Scheer-Senyarich I; Bloch-Queyrat C; Leccia MT; Stefan A; Saiag P; Grange F; Meyer N; de Quatrebarbes J; Dinulescu M; Legoupil D; Machet L; Dereure O; Zehou O; Montaudié H; Wierzbicka-Hainaut E; Le Corre Y; Mansard S; Guégan S; Arnault JP; Dalac S; Aubin F; Alloux C; Lopez I; Cherbal S; Tibi A; Lévy V;
    J Clin Oncol; 2020 Sep; 38(26):3051-3061. PubMed ID: 32730186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Case Report of Unresectable Cutaneous Squamous Cell Carcinoma Responsive to Pembrolizumab, a Programmed Cell Death Protein 1 Inhibitor.
    Chang AL; Kim J; Luciano R; Sullivan-Chang L; Colevas AD
    JAMA Dermatol; 2016 Jan; 152(1):106-8. PubMed ID: 26422398
    [No Abstract]   [Full Text] [Related]  

  • 10. Eruptive squamous cell carcinoma in a patient treated with concomitant pembrolizumab and imiquimod.
    Kanekura T; Arimura A; Kirishima M; Tanimoto A
    J Dermatol; 2019 Dec; 46(12):1202-1204. PubMed ID: 31599020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of response and acquired resistance to the programmed death-1 inhibitor pembrolizumab in Stage III metastatic cutaneous squamous cell carcinoma.
    Zalaudek I; Corneli P; Vernoni S; Fedele D; Papa G; Conforti C; Retrosi C; Vezzoni R; Fagotti S; Longone M; Farinazzo E; di Meo N; Pizzichetta MA
    Dermatol Ther; 2019 Nov; 32(6):e13107. PubMed ID: 31595596
    [No Abstract]   [Full Text] [Related]  

  • 12. Rapid response of metastatic cutaneous squamous cell carcinoma to pembrolizumab in a patient with xeroderma pigmentosum: Case report and review of the literature.
    Deinlein T; Lax SF; Schwarz T; Giuffrida R; Schmid-Zalaudek K; Zalaudek I
    Eur J Cancer; 2017 Sep; 83():99-102. PubMed ID: 28734147
    [No Abstract]   [Full Text] [Related]  

  • 13. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.
    Chen WC; Chu PY; Lee YT; Lu WB; Liu CY; Chang PM; Yang MH
    Medicine (Baltimore); 2017 Dec; 96(52):e9519. PubMed ID: 29384959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab and its use in the treatment of recurrent or metastatic head and neck cancer.
    Sheth S; Weiss J
    Future Oncol; 2018 Jul; 14(16):1547-1558. PubMed ID: 29464975
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Regression of cutaneous basal cell and squamous cell carcinoma under pembrolizumab].
    Delaitre L; Martins-Héricher J; Truchot E; Denis D; Prophette B; Maillard H; Bénéton-Benhard N
    Ann Dermatol Venereol; 2020 Apr; 147(4):279-284. PubMed ID: 31879092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.
    Chow LQM; Haddad R; Gupta S; Mahipal A; Mehra R; Tahara M; Berger R; Eder JP; Burtness B; Lee SH; Keam B; Kang H; Muro K; Weiss J; Geva R; Lin CC; Chung HC; Meister A; Dolled-Filhart M; Pathiraja K; Cheng JD; Seiwert TY
    J Clin Oncol; 2016 Nov; 34(32):3838-3845. PubMed ID: 27646946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
    Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
    Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
    Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
    Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pembrolizumab and concurrent hypo-fractionated radiotherapy for advanced non-resectable cutaneous squamous cell carcinoma.
    Lavaud J; Blom A; Longvert C; Fort M; Funck-Brentano E; Saiag P
    Eur J Dermatol; 2019 Dec; 29(6):636-640. PubMed ID: 31903954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases.
    Borradori L; Sutton B; Shayesteh P; Daniels GA
    Br J Dermatol; 2016 Dec; 175(6):1382-1386. PubMed ID: 27059424
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.